MedTrace Logo

Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

NCT03763370 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-10-15

No results posted yet for this study

Summary

Compassionate use access to belantamab mafodotin (GSK2857916) (in combination with bortezomib/dexamethasone or pomalidomide/dexamethasone) for eligible participants with multiple myeloma previously treated with at least 1 prior line of therapy.

Conditions

Interventions

DRUG

Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)

Drug: Belantamab mafodotin •Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment. Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles Drug: Dexamethasone •Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles

DRUG

Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)

Drug: Belantamab mafodotin: * Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once * Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information Drug: Dexamethasone •Dexamethasone will be administered at every cycle, based on the full prescribing information

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03763370 on ClinicalTrials.gov